Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2008-05-20
2008-05-20
Qian, Celine (Department: 1636)
Chemistry: molecular biology and microbiology
Vector, per se
C536S023100
Reexamination Certificate
active
07374930
ABSTRACT:
This patent discloses compositions and methods of use thereof to normalize the blood glucose levels of patients with type 2 diabetes. It relates particularly to a plasmid comprising a chicken β actin promoter and enhancer; a modified GLP-1 (7-37) cDNA (pβGLP1), carrying a furin cleavage site, which is constructed and delivered into a cell for the expression of active GLP-1.
REFERENCES:
patent: 5545618 (1996-08-01), Buckley et al.
patent: 5614492 (1997-03-01), Habener
patent: 5958909 (1999-09-01), Habener
patent: 5990077 (1999-11-01), Drucker
patent: 5994127 (1999-11-01), Selden et al.
patent: 6048724 (2000-04-01), Selden et al.
patent: 6162907 (2000-12-01), Habener
patent: 6191102 (2001-02-01), DiMarchi
patent: 6217912 (2001-04-01), Park et al.
patent: 6258789 (2001-07-01), German
patent: WO 00/23602 (2000-04-01), None
Miyazaki et al (Gene, 1989, vol. 79, pp. 269-277).
F. Mauvais-Jarvis, et alTherapeutic Perspectives for Type 2 Diabetes Mellitus: Molecular and Clinical Insights, Diabetes Metab (Paris) 2001, 27, 415-423.
Q. Xiao, et alBiological Activities of Glucagon-Like Peptide-1 Analogues in Vitro and in Vivo, Departments of Medicine and Physiology, University of Toronto, Dec. 11, 2000.
Yihong Wang, et al,Glucagon-like Peptide-1 Can Reverse the Age-related Decline in Glucose Tolerance in Rats, The Journal of Clinical Investigation, vol. 99, No. 12, Jun. 1997, 2883-2889.
David G. Parkes, et al,Insulinotropic Actions of Exendin-4 and Glucagon-Like Peptide-1 In Vivo and In Vitro, Metabolism, vol. 50, No. 5 (May 2001), pp. 583-589.
N Dachicourt, et alGlucagon-Like Peptide-1(7-36)-amide confers glucose sensitivity to previously glucose-incompetent β-cells in diabetic rats: in vivo and in vitro studies, Journal of Endocrinology (1997) 155, 369-376.
Francis C. Lynn, et al,Defective Glucose-Dependent Insulinotropic Polypeptide Receptor Expression in Diabetic Fatty Zucker RatsDiabetes, vol. 50, May 2001.
Seamus K, Sreenan, et al,Glucagon-Like Peptide-1 Stimulates Insulin Secretion by a Ca2+-Independent Mechanism in Zucker Diabetic Fatty Rat Islets of LangerhansMechanism, vol. 49, No. 12 (Dec. 2000), pp. 1579-1587.
Philip J. Larsen, et al,Systemic Administration of the Long-Acting GLP-1 Derivative NN2211 Induces Lasting and Reversible Weight Loss in Both Normal and Obese Rats, Diabetes, vol. 50, Nov. 2001.
Laurie Baggio, et al,Glucagon-Like Peptide-1, But Not Glucose-Dependent Insulinotropic Peptide, Regulates Fasting Glycemia and Nonenteral Glucose Clearance in Mice, Endocrinology, vol. 141, No. 10, 2002.
Diane M. Hargrove, et al.Glucose-Dependent Actiopn of Glucagon-Like Peptide-1(7-37)In Vivo During Short- or Long-Term Administration, Metabolism, vol. 44, No. 9 (Sep. 1995), pp. 1231-1237.
Lone Pridal, et alAbsorption of Glucagon-like Peptide-1 Can Be Protracted by Zinc or Protamine, International Journal of Pharmaceutics 136 (1996) 53-59.
Daniel J. Drucker,Minireview: The Glucagon-Like Peptides, Endocrinology, vol. 142, No. 2, 2001.
Riccardo Perfetti, et al,Glucagon-like Peptide-1: a Major Regulator of Pancreatic β-cell Function, European Journal of Endocrinology (2000) 143 717o-725.
Unger, R. H., Eisentraut AM: Entero-insular axis,Arch Intern Med123:261-266, 1969.
Holst JJ: Glucagonlike peptide 1: a newly discovered gastrointestinal hormone.Gastroenterology107:1848-1855, 1994.
Hauck MA. Heimesaat MN, Orskov C, Holst JJ, Ebert R, Creutzfeldt W: Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.J Clin Invest91:301-307, 1993.
Fehmann HC, Goke R, Goke B: Cell and molecular biology of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulin releasing polypeptide.Endocr Rev16:390-410, 1995.
Nauck MA, Sauerwald A, Ritzel R, Holst JJ, Schmiegel W: Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure.Diabetes Care21:1925-1931, 1998.
Rachman J, Barrow BA, Levy JC, Turner RC: Near-normalisation of diurnal glucose concentrations by continuous administration of glucagono-like peptide-1 (GLP-1) in subjects with NIDDM.Diabetologia40:205-211, 1997.
Szayna M, Doiyle ME, Betkey JA, Holloway HW, Spencer RG, Greig NH, Egan JM: Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rate.Endocrinology141:1936-1941, 2000.
DeFronzo, R.A., Bonadonna, Riccardo, C., and Ferrannini, Eleuterio: Pathogenesis of NIDDM: A Precarious Balance between Insulin Action and Insulin Secretion.International Textbook of Diabetes Mellitus, pp. 569-619, 1992.
Suh, W., et al. An Angiogenic, Endothelial-Cell-Targeted Polymeric Gene Carrier. Nov. 2002. vol. 6, No. 5, pp. 664-672.
Mark Gutniak, M.D., et al.,Antidiabetogenic Effect of Glucagon-Like Peptide-1(7-36)amide in Normal Subjects and Patients with Diabetes Mellitus. The New England Journal of Medicine, May 14, 1992.
David M. Nathan, M.D., et al,Insulinotropic Action of Glucagonlike Peptide-1-(7-37)in Diabetic and Nondiabetic Subjects. Diabetes Care, vol. 15, No. 2, Feb. 1992.
M. A. Nauck, et al,Normalization of Fasting Hyperglycaemia by Exogenous Glucagon-Like Peptide 1(7-36 amide)in Type 2(non-insulin-dependent)diabetic Patients, Diabetologia (1993) 36: 741-744.
Mark K. Gutniak, M.D., et al,Potential Therapeutic Levels of Glucagon-Like Peptide 1 Achieved in Humans by a Buccal Tablet, Diabetic Care, vol. 19, No. 8, Aug. 1996.
J F. Todd, et al.Glucagton-like Peptide-1(GLP-1)a trial of treatment in Non-insulin Dependent Diabetes Mellitus, European Journal of Clinical Investigation (1997) 27, 533-536.
Diane M. Hargrove, et al,Glucose-Dependent Action of Glucagon-Like Peptide-1(7-37)In Vivo During Short- or Long-Term Administration, Metabolism, vol. 44, No. 9 (Sep. 1995), pp. 1231-1237.
Mark K. Gutniak, M D. et al,GLP-1 Tablet in Type 2 Diabetes in Fasting and Postprandial Conditions, Diabetes Care, vol. 20, No. 12, Dec. 1997.
Jens Larsen, M.D., et al.Glucagon-Like Peptide-1 Infusion Must Be Maintained for 24 h/day to Obtain Acceptable Glyce3mia in Type 2 Diabetic Patients Who Are Poorly Controlled on Sulphonylurea Treatment, Diabetes Care, vol. 24, No. 8, Aug. 2001.
Tina Vilsboll, et al,Reduced Postprandial Concentrations of Intact Biologically Active Glucagon-Like Peptide 1 in Type 2 Diabetic Patients, Diabetes, vol. 50, Mar. 2001.
Tina Visbol, et al,Evaluation of β-Cell Secretory Capacity Using Glucagon-Like Peptide 1, Diabetes Care, vol. 23, No. 6, Jun. 1, 2000.
Robert Ritzel, et al,Glucagon-Like Peptide 1 Increases Secretory Burst Masds of Pulsatile Insulin Secretion in Patients With Type 2 Diabetes and Impaired Glucose Tolerance, Diabetes. vol. 50, Apr. 2001.
Adrian Vella, et al.Effect of Glucagon-Like Peptide-1(7-36)-Amide on Initial Splanchnic Glu8cose Uptake and Insulin Action in Humans With Type 1 Diabetes, Diabetes. vol. 50, Mar. 2001.
T. Vilsboll, et al,No Reactive Hypoglycaemia in Type 2 Diabetic Patients After Subcutaneous Administration of GLP-1 and Intravenous Glucose, 2001 Diabetes UK. Diabetic Medicine, 18, 144-149.
M. K. Gutniak, et al,Antidiabetogenic Action of Glucagon-Like Peptide-1 Related to Administration Relative to Meal Intake in Subjects with Type 2 Diabetes, Journal of Internal Medicine 2001: 250: 81-87.
Adrian Vella, et al.Effect of Glucagon-Like Peptide-1(7-36)-Amide on Initial Splanchnic Glucose Uptake and Insulin Action in Humans With Type 1 Diabetes, Diabetes, vol. 50, Mar. 2001.
Tina Vilsboll, et al.Evaluation of β-Cell Secretary Capacity Using Glucagon-Like Peptide 1, Diabetes Care, vol. 23, No. 6, Jun. 2000.
C. B. Juhl, et al.Short-term Treatment with GLP-1 Increases Pulsatile Insulin Secretion in Type II Diabetes with No Effect On Orderliness, Diabetologia (2000) 43: 583-588.
C. Hedetoft, et al.Effect of Glucagon-Like Peptide 1(7-36)Amide in Insulin-Treated Patients with Diabetes Mellitus Secondary to Chronic Pancreatitis, Pancreas vol. 20, No. 1, pp. 25-31, 2000.
E. Mannucci, et al.Glucagon-Like Peptide(GLP)-1 and Leptin Concentrations in Obese Patients w
Ko Kyungsoo
Lee Min-hyung
Oh Seungjoon
Expression Genetics, Inc.
Qian Celine
Thorpe North & Western LLP
LandOfFree
GLP-1 gene delivery for the treatment of type 2 diabetes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with GLP-1 gene delivery for the treatment of type 2 diabetes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and GLP-1 gene delivery for the treatment of type 2 diabetes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2801231